Lipophilic analogs of isoniazid with antiproliferative in vitro activity-VIII

Medicinal Chemistry Research

Volumn 9, Issue 5, 1999, Pages 306-321

  Vigorita, Maria Gabriella ^a   Maccari, Rosanna ^a   Ottanà, Rosaria ^a   Monforte, Francesca ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BREFELDIN A; ISONIAZID DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CYTOTOXICITY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIPOPHILICITY;

EID: 0032726564     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Presented in part at the First Italian-Swiss Meeting on Medicinal Chemistry, Torino, Italy, September 1997.
2. a) Rastogi N., Goh K.S., Antimicrob. Agents Chemother., 1990, 34, 2061-2064
3. th Ed., Ed. by M.E. Wolff, John Wiley & Sons, Inc., pp. 575-635, 1996
4. a) Vigorita M.G., Basile M., Zappalà C., Gabbrielli G., Pizzimenti F., Il Farmaco, 1992, 47, 893-906
5. b) Vigorita M.G., Ottanà R., Zappalà C., Maccari R., Pizzimenti F.C., Gabbrielli G., Il Farmaco, 1994, 49, 775-781
6. c) Vigorita M.G., Ottanà R., Zappalà C., Maccari R., Pizzimenti F.C., Gabbrielli G., Il Farmaco, 1995, 50, 783-786
7. Vigorita M.G., Ottanà R., Maccari R., Monforte F., Bisignano G., Pizzimenti F.C., Boll. Chim. Farm., 1998, 137, 267-276.
8. a) Sood C.K., Sood A., Spielvogel B.F., Yousef J.A., Burnham B., Hall I.H., J. Pharm. Sci., 1991, 80, 1133-1140;
9. b) Spielvogel B.F., Sood A., Morse K.W., Wong O.T., Hall I.H., Pharmazie, 1991, 46, 592-594.
10. a) Boyd M.R., Principles and Practices of Oncology, 1989, 3, 1-12
11. b) Grever M.R., Schepartz S.A., Chabner B.A., Seminars in Oncology, 1992, 19, 622-638.
12. Ottanà R., Rotondo E., Vigorita M.G., Zappalà C., Giordano G., Heterocycles, 1994, 38, 2389-2399.
13. Ottanà R., Maccari R., Vigorita M.G., Rotondo E., J. Chem. Res. (S), 1998, 550-551, (M) 2532-2544.
14. Weislow O.S., Kiser R., Fine D.L., Bader J., Shoemaker R.H., Boyd M.R., J. Natl. Cancer Inst., 1989, 81, 577-58.
15. Dimmock J.R., Kumar P., Allen T.M., Kao G.Y., Haneran S., Balzarini J., De Clercq E., Pharmazie, 1997, 52, 182-186.
16. Personal comunications
17. Boyd M.B., Paull K.D., Drug Development Res., 1995, 34, 91-109.
18. a) Rialet V., Meijer L., Anticancer Res., 1991, 11, 1581-1590
19. b) Baratte B., Meijer L., Galktionov K., Beach D., Anticancer Res., 1992 12, 873-880.
20. a) Nurse P., Nature, 1990, 344, 503-508
21. b) Morgan D.O., ibidem, 1995, 374, 131-134
22. c) Marx J., Science, 1994, 264, 344-345
23. d) Motokura T., Arnold A., Biochim. Biophys. Acta, 1993, 1155, 63-68
24. e) Hunter T., Pines J., Cell, 1994, 79, 573-582
25. f) Hartwell L.H., Kastan M.B., Science, 1994, 266, 1821-1828.
26. a) Guo H., Tittle T.V., Allen H. Maziarz R.T., Exp. Cell Res. 1998, 245, 57-68
27. b) Salomons F.A., van der Klei I.J., Kram A.M., Harder W., Veenhuis M., FEBS Lett., 1997, 411, 133-139.
28. a) Tomlison E., J. Chromat., 1975, 113, 1-45
29. b) Biagi G.L., Recanatini M., Barbero A.M., Guerra M.C., Sapone A., Brca P.A., Pietrogrande M.C., Cromatographic Rm Values as Lipophilicity Index in QSAR: Rational Approach to the Design of Bioactive Compounds, C. Silipo and A. Vittoria eds., Elsevier Science Publishers B.V. Amsterdam, pp. 83-90, 1991.
30. Hollingshead M.G., Alley M.C., Camalicr R.F., Abbott B.J., Mayo J.G., Malspeis L., Grever M.R., Life Sciences, 1995, 57, 131-141.